Baird Maintains Humana(HUM.US) With Hold Rating, Maintains Target Price $374
Hold Rating on Humana Amid Potential MLR Pressures and Strategic Mitigations
Mizuho Securities Cuts Humana's Price Target to $305 From $410
Humana Is Maintained at Hold by Truist Securities
Oppenheimer Maintains Humana(HUM.US) With Buy Rating, Maintains Target Price $280
Truist Financial Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $260
Humana (HUM) Receives a Rating Update From a Top Analyst
Humana Is Maintained at Equal-Weight by Barclays
Humana Analyst Ratings
CVS Health Upgraded at Barclays on Medicare Prospects
JPMorgan Adjusts Price Target on Humana to $254 From $396, Maintains Neutral Rating
Barclays Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $250
Humana Raised to Outperform From Market Perform by Bernstein
Humana Is Maintained at Outperform by RBC Capital
Humana Analyst Ratings
RBC Capital Maintains Humana(HUM.US) With Buy Rating, Cuts Target Price to $265
RBC Cuts Price Target on Humana to $265 From $400, Keeps Outperform Rating
RBC Capital Reaffirms Their Buy Rating on Humana (HUM)
Cognizant's Revenue Outlook: A Hold Rating Amidst Humana's Anticipated Spending Changes
Bernstein Upgrades Humana(HUM.US) to Buy Rating, Cuts Target Price to $308